The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer

Jens Geginat, Paola Larghi, Moira Paroni, Giulia Nizzoli, Alessandra Penatti, Massimiliano Pagani, Nicola Gagliani, Pierluigi Meroni, Sergio Abrignani, Richard A. Flavell

Research output: Contribution to journalArticlepeer-review


Interleukin-10 (IL-10) is known to be a tolerogenic cytokine since it inhibits pro-inflammatory cytokine production and T cell stimulatory capacities of myeloid cells, such as macrophages and dendritic cells. In particular, it has a non-redundant tolerogenic role in intestinal immune homeostasis, since mice and patients with genetic defects in the IL-10/IL-10R pathway develop spontaneously colitis in the presence of a normal intestinal flora. However, IL-10 is also a growth and differentiation factor for B-cells, can promote autoantibody production and has consequently a pathogenic role in systemic lupus erythematosus. Moreover, IL-10 can promote cytotoxic T-cell (CTL) responses and this immunogenic activity might be relevant in type-1 diabetes and anti-tumor immune responses. This review summarizes these paradoxic effects of IL-10 on different types of immune responses, and proposes that different cellular sources of IL-10, in particular IL-10-secreting helper and regulatory T-cells, have different effects on B-cell and CTL responses. Based on this concept we discuss the rationales for targeting the IL-10 pathway in immune-mediated diseases and cancer.

Original languageEnglish
JournalCytokine and Growth Factor Reviews
Publication statusAccepted/In press - Jan 28 2016


  • Cancer
  • Colitis
  • Interleukin-10
  • Systemic lupus erythematosus
  • T-cells

ASJC Scopus subject areas

  • Immunology
  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer'. Together they form a unique fingerprint.

Cite this